- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03105193
Intravenous and Intraperitoneal Lignocaine for Perioperative Analgesia in Laparoscopic Colon Resections
The aim of this study is to investigate the analgesic effects of intraperitoneal lignocaine (IPL) compared with intravenous lignocaine (IVL) after laparoscopic colon resections. We plan to run a 2 group randomized, double blind, clinical trial which will look into morphine consumption as the primary outcome.
Group 1 (IV lignocaine)- IV bolus of lignocaine and a 3 day post operative IV lignocaine infusion. Intra peritoneal (IP) bolus of normal saline + 3 day post operative IP normal saline infusion
Group 2 (IP lignocaine)- IV bolus of normal saline and a 3 day post operative IV normal saline infusion. IP bolus of lignocaine + 3 day post operative IP lignocaine infusion
Study Overview
Status
Detailed Description
Over the last 20 years, laparoscopic colonic surgery has become an accepted first-line treatment for colon cancer. A population-based study showed that laparoscopic colonic resections can be performed with lower hospital costs up to 90 days after discharge when compared to open surgery. Laparoscopic colonic resections have also been associated with fewer postoperative complications and lower mortality.
New Zealand has one of the highest rates of bowel cancer in the world, and it is the second highest cause of cancer deaths in New Zealand. With the implementation of a bowel screening programme in New Zealand, the projected numbers of stage 1 bowel cancers are expected to increase. More avenues to improve perioperative care need to be explored to improve patient outcomes.
Controlling postoperative pain effectively has been shown to reduce the length of hospital stay and improve patient/clinical outcomes. Opioids work as μ-receptor agonists in the spinal cord and brain, and although opioids are excellent at reducing pain, they are associated with nausea, vomiting, dizziness, decreased blood pressure, and urinary retention. Epidurals have been incorporated into Enhanced Recovery After Surgery protocols for controlling post-operative pain. However, epidurals are an invasive procedure with significant side effects such as hypotension, urinary retention, respiratory depression, motor blockade and rarely epidural abscess and meningitis. It has also been shown that up to 30 percent of epidural catheters dislodge, block or leak. These complications have led to a movement towards other regional analgesia techniques which allow local anaesthetic (LA) to target the abdominal wound specifically.
Intraperitoneal local anaesthetic (IPLA) has shown promise in reducing pain after colonic surgery with a meta-analysis9, and a recent IPLA colorectal study conducted at Counties Manukau health showing that it reduces pain and opioid use over and above the effect of an epidural10, which is primarily aimed at the abdominal wound. After an IPLA bolus serum local anaesthetic levels are detectable within 2 minutes. Some studies show reduced early postoperative pain and opioid consumption with intravenous lignocaine infusion alone. The question remains however if there is a benefit from using intraperitoneal local anaesthetic compared to administering it intravenously as the IPLA should block both the intraabdominal wound, via a local action, and the skin wound via a systemic action.. This has been investigated in four studies, however none of these studies compared intravenous local anaesthetic (IVLA) and IPLA for colon resection.
The aim is that, by optimising analgesia regimes using local anaesthetic, we can improve patient experience of pain and recovery thereby achieving an earlier discharge and early recovery from surgery. This has significant economic benefits for all involved.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Auckland, New Zealand
- Manukau Surgical Centre, Middlemore Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- consecutive consenting patients undergoing elective laparoscopic colonic resections will be recruited from surgical outpatient clinics at Manukau Super Clinic.
Exclusion Criteria:
- under 16 years of age
- acute colonic resection
- those with ASA >= 4
- previous adverse reaction/allergy to local anaesthetic,
- surgery for rectal lesions which was defined as lesion within 15 cm of the anal verge
- preoperative systemic steroid dependence
- hepatic dysfunction, opioid use greater than 6 months
- a diagnosis of Chronic Pain Syndrome
- inability to consent or complete data scores in the study questionnaires due to cognitive impairment and/or language barrier.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intraperitoneal Lignocaine
IP Lignocaine
|
Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump
Intraperitoneal bolus of lignocaine down first port site.
3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon.
Infusion will be administered by ambit pump.
|
Experimental: Intravenous lignocaine
IV lignocaine
|
Intraperitoneal bolus of normal saline down first port site.
3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon.
Infusion will be administered by ambit pump.
Other Names:
Intravenous lignocaine bolus at induction.
3 day postoperative IV infusion of lignocaine administered by ambit pump
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Morphine consumption
Time Frame: 3 days
|
Total morphine consumption at day 3
|
3 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain scores
Time Frame: 0, 6, 12 hours and Postoperative day (POD) 1, 2, 3, 4 and 7
|
Pain scores using the visual analogue score (VAS)
|
0, 6, 12 hours and Postoperative day (POD) 1, 2, 3, 4 and 7
|
Systemic Inflammatory Response (CRP and WBC)
Time Frame: very morning post op starting day 1 until day 4 post op
|
Blood test
|
very morning post op starting day 1 until day 4 post op
|
Systemic Local Anesthetic Level
Time Frame: every morning post op starting day 1 until day 4 post op
|
Blood test
|
every morning post op starting day 1 until day 4 post op
|
Length of stay
Time Frame: Variable measure as it is dependent on the patients recovery after surgery. Cut off 3 weeks
|
The day that the patient is discharged will be recorded
|
Variable measure as it is dependent on the patients recovery after surgery. Cut off 3 weeks
|
Return of bowel function
Time Frame: Variable measure as it is dependent on the patients recovery after surgery. Cut off 3 weeks
|
Time to flatus, first bowel motion
|
Variable measure as it is dependent on the patients recovery after surgery. Cut off 3 weeks
|
Readmissions complications
Time Frame: 30 days post op
|
Readmissions complications will be recorded up to day 30 post op using the Clavien-Dindo Classification
|
30 days post op
|
Surgical recovery scores (SRS)
Time Frame: Up to 60 days post op
|
SRS questionnaires will be administered at day 1 till discharge then POD 14, 30 and 60
|
Up to 60 days post op
|
Collaborators and Investigators
Investigators
- Principal Investigator: Andrew G Hill, The University of Auckland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Perceptual Disorders
- Agnosia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
- IPL/IVL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Laparoscopic Colon Resection
-
Exero Medical Ltd.CompletedOpen/ Laparoscopic/ Robotic Resection of the ColonIsrael
-
hui houNot yet recruitingLaparoscopic Liver Resection | Open Liver ResectionChina
-
Assiut UniversityNot yet recruitingLaparoscopic Liver ResectionEgypt
-
Hartford HospitalCubist Pharmaceuticals LLCCompleted
-
Duke UniversityTerminatedLaparoscopic Colorectal ResectionUnited States
-
University of Roma La SapienzaCompletedColorectal Laparoscopic ResectionItaly
-
The Second Hospital of Anhui Medical UniversityRecruitingLaparoscopic Liver Resection | Enhanced Recovery | Hepatolithiasis | Open Liver ResectionChina
-
hui houUnknownLaparoscopic Liver Resection | Vascular Occlusion | TourniquetChina
-
Allina Health SystemCompletedColon ResectionUnited States
-
Ethicon Endo-SurgeryCompletedLeft-sided Colon ResectionUnited States, United Kingdom, Belgium, Germany, Spain
Clinical Trials on IV Saline bolus and infusion
-
University of CalgaryNot yet recruitingPostural Orthostatic Tachycardia Syndrome | Post Acute Sequelae of SARS CoV 2 Infection
-
Aretaieion University HospitalRecruitingPain, Postoperative | Analgesia | Pain, Acute | Magnesium | Pain, NociceptiveGreece
-
Second Affiliated Hospital of Wenzhou Medical UniversityRecruiting
-
Alloksys Life Sciences B.V.Aix ScientificsCompleted
-
Bioblast Pharma Ltd.ParexelCompletedHealthy Volunteer SubjectsUnited States
-
Qpex Biopharma, Inc.Biomedical Advanced Research and Development AuthorityCompletedBacterial InfectionsUnited States
-
University of Alabama at BirminghamTerminatedGynecologic CancerUnited States
-
Aarhus University HospitalTerminatedAcute Kidney Injury | Fluid Overload | HypoperfusionDenmark
-
University of VirginiaThe University of QueenslandCompletedPlasma Concentration of AntibioticsUnited States
-
Milton S. Hershey Medical CenterWithdrawnSurgical Site Infections